Deadly Blood Clots Have Stopped Since Under-40s Advised Not to Have AstraZeneca Jab
Which would imply AstraZeneca was indeed the cause?
Deadly blood clots have stopped completely since the under-40s were advised not to have the AstraZeneca Covid vaccine, experts have found.
On May 7, the Joint Committee on Immunisation and Vaccination (JCVI) ruled that younger people should be offered an alternative jab because the risk of a dangerous clot outweighed the benefit.
They found that the condition usually occurs between five and 30 days after vaccination, and said the number of cases had “dramatically reduced” since the first week of June, with no new cases for nearly a month.
Dr Sue Pavord, of Oxford University Hospitals NHS Foundation Trust, who led the research team, said: “Thankfully that surge of cases is now largely over, and we haven’t really seen a new case of it since probably about three or four weeks ago.”
The deadly clotting condition has now been named vaccine-induced immune thrombocytopenia and thrombosis (VITT), and researchers have identified a list of criteria for diagnosing the condition.
The team found the average onset time was 14 days after the AstraZeneca jab, but said they had discovered no underlying factor that made people more susceptible. They also pointed out that although there was just a one in 50,000 chance of developing a clot after the vaccine, the chance of death was high.
Nearly one in four – 23 per cent – of those admitted with the condition in Britain died, many of whom were young and healthy. [AKA people who wouldn’t have died of COVID in a million years.] For those who developed a clot in the brain or other organs and had low blood counts, the risk of death rose to 80 per cent.
“This is something new and something very severe,” said Michael Makris, professor of haemostasis and thrombosis at the University of Sheffield.
Experts said it was “striking” how different the patients were from usual blood clot victims, with 50 per cent having no previous medical illness at all. Some 85 per cent of patients were under 60, with an average age of 48.
“That’s despite the UK vaccine rollout beginning in the older age groups and working down in order of age,” added Dr Pavord. “So by this time of our study not many people in their 20s and 30s had actually been given the AstraZeneca vaccine.
“For those who develop VITT, it can be devastating – it often affects young, otherwise healthy vaccine recipients and has high mortality.”
However, the experts said cases had largely stopped since the JCVI ruling. Prof Makris explained: “In practice, what has happened since about June 7 is the number of cases in the UK has dramatically reduced. We hardly really see any new cases, and even with the second dose vaccine the number of cases we have seen is tiny.”
Despite this, the researchers are concerned that early cases in older people may have been missed.
They are now looking back to see whether more people have been impacted after discovering that the condition can cause blocking of the arteries, which can lead to a heart attack or a stroke. Currently, the incidence of VITT is thought to be one in 100,000 in older people, but may turn out to be higher.
Dr Catherine Bagot, consultant haematologist at Glasgow Royal Infirmary, said: “From Jan 6 until we recognised this condition in the middle of the March, we were vaccinating huge number of elderly patients, and it might be that in an older patient who develops a stroke or develops a cerebral vein thrombosis, you might think well that’s just what it is.
“So in Scotland, we’re doing a look back at all stroke patients to see what their relationship was to the vaccine so we can try and work out possibly more accurately what the incidence might be in the older population.”
The research was published in the New England Journal of Medicine.
Source: The Telegraph